BY IDA JORGENSEN
-
Chemometec rises from downturn – further growth is in store
It’s difficult to locate various other clinical tool firms that are expanding as quick as Danish Chemometec is right currently, claims expert.
-
Analyst: Novo Nordisk shows “decisiveness” by dropping partner after dispute over generic drugs
Novo Nordisk goes down Hims & Hers offer adhering to accusations of prohibited sales. The choice is creating “sound” around Novo Nordisk’s placement in the U…
-
Professor on Lars Rebien’s power in the Novo Group: “The return of the king”
It’s clear that Lars Rebien Sørensen is foretelling throughout the whole Novo Team after signing up with the business board, states teacher, highlighting that this can be tro…
-
Former CEO wins bidding war for 23andMe
With a proposal of USD 305m, the founder and previous chief executive officer of 23andMe, Anne Wojcicki, will certainly think possession of the insolvent firm.
-
Bavarian Nordic scores top price for priority voucher – was not pressured into a quick sale by shareholders
According to the CFO, the pharmaceutical firm was come close to by numerous possible customers.
-
Former CEO wins bidding war for 23andMe
With a bid of USD 305m, the co-founder and former CEO of 23andMe, Anne Wojcicki, will assume ownership of the bankrupt company.
-
Roche to test Parkinson’s drug in phase 3 trial despite previous study failures
Over a years earlier, the Swiss pharmaceutical firm safeguarded legal rights to the prospect from Ireland’s Prothena, which has actually been tormented by current frustration…
-
Report shows China’s potential to beat the US in biotech
Biotechnology as a nationwide approach in the USA has actually been ignored contrasted to even more “captivating” modern technologies, writers of the record claim.
-
No explanation: WSA and owners scant with info about board changes
Neither WSA neither the hearing business’s bulk proprietor will certainly divulge the factor for the Widex successor’s board departure. The adjustment was intended, the…
-
Roche takes promising antibiotic candidate into late-stage trials
Very early research studies reveal that it has the possible to deal with a typical superbug that has actually come to be immune to various other therapies.
